ECSP15026557A - Compuestos y sus métodos de empleo - Google Patents
Compuestos y sus métodos de empleoInfo
- Publication number
- ECSP15026557A ECSP15026557A ECIEPI201526557A ECPI201526557A ECSP15026557A EC SP15026557 A ECSP15026557 A EC SP15026557A EC IEPI201526557 A ECIEPI201526557 A EC IEPI201526557A EC PI201526557 A ECPI201526557 A EC PI201526557A EC SP15026557 A ECSP15026557 A EC SP15026557A
- Authority
- EC
- Ecuador
- Prior art keywords
- compounds
- methods
- inhibit glutaminase
- cancer
- employing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
En la presente se describen compuestos y composiciones que comprenden compuestos que inhiben la glutaminasa. En la presente también se describen métodos para emplear los compuestos que inhiben la glutaminasa en el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/085023 WO2014079011A1 (en) | 2012-11-22 | 2012-11-22 | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
PCT/CN2013/000294 WO2014079136A1 (en) | 2012-11-22 | 2013-03-15 | Compounds, pharmaceutical compositions and uses as glutaminase inhibitors for treating cancers thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP15026557A true ECSP15026557A (es) | 2016-01-29 |
Family
ID=50775393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECIEPI201526557A ECSP15026557A (es) | 2012-11-22 | 2015-06-22 | Compuestos y sus métodos de empleo |
Country Status (36)
Country | Link |
---|---|
US (2) | US10087172B2 (es) |
EP (2) | EP3456719A1 (es) |
JP (2) | JP6333277B2 (es) |
KR (1) | KR20150085079A (es) |
CN (2) | CN108727307A (es) |
AR (1) | AR093598A1 (es) |
AU (2) | AU2013347771B2 (es) |
BR (1) | BR112015011830A2 (es) |
CA (1) | CA2893510C (es) |
CL (1) | CL2015001392A1 (es) |
CR (1) | CR20150316A (es) |
CY (1) | CY1120581T1 (es) |
DK (1) | DK2922850T3 (es) |
EA (2) | EA030646B1 (es) |
EC (1) | ECSP15026557A (es) |
ES (1) | ES2690390T3 (es) |
HK (1) | HK1214593A1 (es) |
HR (1) | HRP20181628T1 (es) |
HU (1) | HUE040111T2 (es) |
IL (1) | IL238958B (es) |
LT (1) | LT2922850T (es) |
MX (1) | MX367389B (es) |
MY (1) | MY177344A (es) |
NZ (1) | NZ708382A (es) |
PE (1) | PE20151072A1 (es) |
PH (2) | PH12015501150B1 (es) |
PL (1) | PL2922850T3 (es) |
PT (1) | PT2922850T (es) |
RS (1) | RS57859B1 (es) |
SA (1) | SA515360469B1 (es) |
SG (2) | SG11201504049VA (es) |
SI (1) | SI2922850T1 (es) |
TR (1) | TR201812360T4 (es) |
TW (2) | TW201906825A (es) |
UA (1) | UA117360C2 (es) |
WO (3) | WO2014079011A1 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
LT2920168T (lt) | 2012-11-16 | 2021-10-25 | Calithera Biosciences, Inc. | Heterociklinis gliutaminazės inhibitorius |
KR20150085078A (ko) | 2012-11-21 | 2015-07-22 | 아지오스 파마슈티컬스 아이엔씨. | 글루타마제 억제제 및 사용 방법 |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
AU2013356241A1 (en) * | 2012-12-03 | 2015-07-09 | Calithera Biosciences, Inc. | Treatment of cancer with heterocyclic inhibitors of glutaminase |
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
CN111393431A (zh) | 2014-01-06 | 2020-07-10 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
MX2016012244A (es) * | 2014-03-21 | 2017-05-08 | Agios Pharmaceuticals Inc | Compuestos y sus metodos de uso. |
MA39926B1 (fr) | 2014-04-30 | 2019-12-31 | Pfizer | Dérivés de dihétérocycle liés à cycloalkyle |
GB201409624D0 (en) | 2014-05-30 | 2014-07-16 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
AU2015283850B2 (en) | 2014-07-03 | 2020-06-04 | Board Of Regents, University Of Texas System | GLS1 inhibitors for treating disease |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
WO2016014890A1 (en) * | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
SG11201700816YA (en) | 2014-08-07 | 2017-02-27 | Calithera Biosciences Inc | Crystal forms of glutaminase inhibitors |
US10245254B2 (en) | 2014-10-03 | 2019-04-02 | University of Pittsburgh—of the Commonwealth System of Higher Education | Glutaminase inhibitors |
KR20170132333A (ko) | 2015-04-06 | 2017-12-01 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 글루타미나제 억제제에 의한 폐암의 치료 |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
WO2017004359A1 (en) * | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
AU2016335991A1 (en) | 2015-10-05 | 2018-05-10 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
TW201731511A (zh) * | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
CN109503570B (zh) * | 2015-12-18 | 2020-08-25 | 诺言医药科技(上海)有限公司 | 一种含有索拉非尼的药物组合物及其应用 |
WO2017112831A1 (en) | 2015-12-22 | 2017-06-29 | Board Of Regents, The University Of Texas System | Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide |
SG11201901389XA (en) | 2016-08-25 | 2019-03-28 | Calithera Biosciences Inc | Combination therapy with glutaminase inhibitors |
CN109982703A (zh) | 2016-08-25 | 2019-07-05 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶抑制剂的组合疗法 |
RU2020112558A (ru) | 2017-10-18 | 2021-11-18 | Боард Оф Регентс, Зе Юниверсити Оф Тексас Систем | Терапия на основе ингибитора глутаминазы |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
WO2020096916A2 (en) | 2018-11-08 | 2020-05-14 | Merck Sharp & Dohme Corp. | Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection |
US20220400732A1 (en) * | 2019-03-21 | 2022-12-22 | Cornell University | Anti-fructose therapy for colorectal and small intestine cancers |
CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
CN112898200A (zh) * | 2021-01-20 | 2021-06-04 | 都创(上海)医药科技股份有限公司 | 5-溴-6-甲氧基吡啶-2-羧酸酯的合成方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
US4070400A (en) | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
SU1761672A1 (ru) * | 1990-05-22 | 1992-09-15 | Белгородский технологический институт строительных материалов им.И.А.Гришманова | Способ получени тонкодисперсного мела |
ES2152310T3 (es) | 1993-03-29 | 2001-02-01 | Basf Ag | Derivados de 1-amino-3-fenoxipropano como moduladores de la resistencia a multiples a farmacos. |
US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
CA2332325A1 (en) * | 1998-06-18 | 1999-12-23 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
US20030054985A1 (en) | 2000-02-22 | 2003-03-20 | Stuart Aaronson | N-cadherin modulated migration, invasion, and metastasis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
US6451828B1 (en) * | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
ATE261126T1 (de) | 2002-08-01 | 2004-03-15 | Mtm Lab Ag | Verfahren für lösung-basierte diagnose |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
ATE477495T1 (de) | 2005-03-16 | 2010-08-15 | Osi Pharm Inc | Biologische marker prediktiv für das ansprechen von krebs auf inhibitoren der kinase des rezeptors für epidermalen wachstumsfaktor |
US8716472B2 (en) | 2006-10-16 | 2014-05-06 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
CN101932605B (zh) | 2007-11-19 | 2014-06-11 | 健泰科生物技术公司 | 用于抑制肿瘤进展的组合物和方法 |
JP2011516826A (ja) | 2008-03-07 | 2011-05-26 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 間葉系様腫瘍細胞またはこの形成を阻害する作用剤の同定のための方法 |
EP2399129B1 (en) | 2009-02-20 | 2015-11-25 | Michael P. Lisanti | A method of diagnosis or prognosis of a neoplasm comprising determining the level of expression of a protein in stromal cells adjacent to the neoplasm |
US10532034B2 (en) | 2009-03-25 | 2020-01-14 | Cornell University | Inhibition of glutaminase C |
US20120142028A1 (en) | 2009-04-17 | 2012-06-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
WO2011143160A2 (en) * | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
WO2011163332A2 (en) | 2010-06-23 | 2011-12-29 | University Of Louisville Research Foundation, Inc. | Methods for detecting cancer |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
UY33930A (es) | 2011-03-04 | 2012-10-31 | Novartis Ag | Inhibidores novedosos de quinasas |
CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
EA201692166A1 (ru) * | 2011-11-21 | 2017-07-31 | Калитера Байосайенсиз Инк. | Гетероциклические ингибиторы глютаминазы |
WO2013138790A1 (en) | 2012-03-15 | 2013-09-19 | Research Foundation Of State University Of New York | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
KR20150085078A (ko) | 2012-11-21 | 2015-07-22 | 아지오스 파마슈티컬스 아이엔씨. | 글루타마제 억제제 및 사용 방법 |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014138391A1 (en) | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
CN111393431A (zh) | 2014-01-06 | 2020-07-10 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
MX2016012244A (es) | 2014-03-21 | 2017-05-08 | Agios Pharmaceuticals Inc | Compuestos y sus metodos de uso. |
-
2012
- 2012-11-22 WO PCT/CN2012/085023 patent/WO2014079011A1/en active Application Filing
-
2013
- 2013-03-15 WO PCT/CN2013/000294 patent/WO2014079136A1/en active Application Filing
- 2013-11-21 PL PL13857585T patent/PL2922850T3/pl unknown
- 2013-11-21 ES ES13857585.7T patent/ES2690390T3/es active Active
- 2013-11-21 LT LTEP13857585.7T patent/LT2922850T/lt unknown
- 2013-11-21 JP JP2015543242A patent/JP6333277B2/ja not_active Expired - Fee Related
- 2013-11-21 EP EP18183580.2A patent/EP3456719A1/en not_active Withdrawn
- 2013-11-21 BR BR112015011830A patent/BR112015011830A2/pt not_active Application Discontinuation
- 2013-11-21 SI SI201331140T patent/SI2922850T1/sl unknown
- 2013-11-21 MY MYPI2015001355A patent/MY177344A/en unknown
- 2013-11-21 PE PE2015000674A patent/PE20151072A1/es unknown
- 2013-11-21 CN CN201810824418.2A patent/CN108727307A/zh active Pending
- 2013-11-21 EA EA201590987A patent/EA030646B1/ru not_active IP Right Cessation
- 2013-11-21 PT PT13857585T patent/PT2922850T/pt unknown
- 2013-11-21 EP EP13857585.7A patent/EP2922850B1/en active Active
- 2013-11-21 WO PCT/CN2013/001428 patent/WO2014079150A1/en active Application Filing
- 2013-11-21 SG SG11201504049VA patent/SG11201504049VA/en unknown
- 2013-11-21 SG SG10201609940RA patent/SG10201609940RA/en unknown
- 2013-11-21 NZ NZ708382A patent/NZ708382A/en unknown
- 2013-11-21 RS RS20181133A patent/RS57859B1/sr unknown
- 2013-11-21 MX MX2015006493A patent/MX367389B/es active IP Right Grant
- 2013-11-21 UA UAA201506066A patent/UA117360C2/uk unknown
- 2013-11-21 DK DK13857585.7T patent/DK2922850T3/en active
- 2013-11-21 TR TR2018/12360T patent/TR201812360T4/tr unknown
- 2013-11-21 KR KR1020157016414A patent/KR20150085079A/ko not_active Application Discontinuation
- 2013-11-21 AU AU2013347771A patent/AU2013347771B2/en not_active Ceased
- 2013-11-21 CA CA2893510A patent/CA2893510C/en active Active
- 2013-11-21 EA EA201890754A patent/EA201890754A1/ru unknown
- 2013-11-21 HU HUE13857585A patent/HUE040111T2/hu unknown
- 2013-11-21 US US14/646,634 patent/US10087172B2/en active Active
- 2013-11-21 CN CN201380070365.5A patent/CN104936954B/zh not_active Expired - Fee Related
- 2013-11-22 TW TW107111990A patent/TW201906825A/zh unknown
- 2013-11-22 TW TW102142566A patent/TWI629268B/zh not_active IP Right Cessation
- 2013-11-22 AR ARP130104322A patent/AR093598A1/es unknown
-
2015
- 2015-05-21 IL IL238958A patent/IL238958B/en not_active IP Right Cessation
- 2015-05-22 PH PH12015501150A patent/PH12015501150B1/en unknown
- 2015-05-22 CL CL2015001392A patent/CL2015001392A1/es unknown
- 2015-05-22 SA SA515360469A patent/SA515360469B1/ar unknown
- 2015-06-15 CR CR20150316A patent/CR20150316A/es unknown
- 2015-06-22 EC ECIEPI201526557A patent/ECSP15026557A/es unknown
-
2016
- 2016-03-04 HK HK16102486.9A patent/HK1214593A1/zh not_active IP Right Cessation
-
2017
- 2017-11-24 PH PH12017502141A patent/PH12017502141A1/en unknown
-
2018
- 2018-04-24 JP JP2018082754A patent/JP2018150316A/ja active Pending
- 2018-04-30 AU AU2018202954A patent/AU2018202954A1/en not_active Abandoned
- 2018-08-17 CY CY20181100864T patent/CY1120581T1/el unknown
- 2018-08-21 US US16/107,220 patent/US10689375B2/en active Active
- 2018-10-10 HR HRP20181628TT patent/HRP20181628T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP15026557A (es) | Compuestos y sus métodos de empleo | |
CL2019000511A1 (es) | Inhibidores de procesos metabólicos celulares. | |
CL2018001134A1 (es) | Composiciones y métodos para inhibir la actividad arginasa | |
CR20150571A (es) | Compuestos y composiciones terapéuticos | |
CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
CL2016001082A1 (es) | Proceso para la síntesis de un inhibidor de indolamina 2,3-dioxigenasa | |
CL2016000807A1 (es) | Amino heteroarilo benzamidas como inhibidores de quinasa. | |
CR20160069A (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
CL2015002194A1 (es) | Inhbidores de erk y sus usos | |
BR112015011756A2 (pt) | inibidores da glutamase e métodos de uso | |
CL2015002151A1 (es) | Biaril amide compuestos como inhibidores de quinasa | |
CL2013002898A1 (es) | Compuestos derivados de benceno sustituido con arilo o heteroarilo; composicion farmaceutica que los comprende y uso en el tratamiento del cancer. | |
CL2016001609A1 (es) | Composiciones farmacéuticas que comprenden azd9291. | |
CL2014001793A1 (es) | Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer. | |
UY34538A (es) | Heteroarilos y usos de los mismos | |
CL2016003260A1 (es) | Profármacos de gemcitabina | |
CL2017000576A1 (es) | Inhibidores de mk2 y sus usos | |
CL2014001865A1 (es) | Compuestos derivados de fosfatos; procedimiento de preparacion; composiciones farmaceuticas que los contienen y uso en el tratamiento del cancer. | |
MX2015011897A (es) | Profarmacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
CL2015002571A1 (es) | Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático. | |
CL2015003704A1 (es) | Péptidos y peptidomiméticos en usos de combinación y tratamientos para la subpoblacion de pacientes con cáncer | |
CL2015001246A1 (es) | Derivados de bendamustina y los metodos de su uso | |
BR112016017112A2 (pt) | Composições de apilimod e métodos de uso das mesmas | |
UY34636A (es) | Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso | |
CL2015000976A1 (es) | Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados. |